Omburtamab for treating relapsed neuroblastoma [ID1664]
In development
Reference number: GID-TA10608
Expected publication date: TBC
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of omburtamab I-131 for treating relapsed neuroblastoma.
Please note that following on from information received from the company, the timelines for this appraisal will be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course.
NICE will continue to monitor any developments and will update interested parties as and when the situation changes.